[HTML][HTML] Applying PET-CT for predicting the efficacy of SBRT to inoperable early-stage lung adenocarcinoma: A Brazilian case-series

FY Moraes, CECV Abreu, GSM Siqueira… - The Lancet Regional …, 2022 - thelancet.com
Background Stereotactic body radiotherapy (SBRT) is a treatment option for early-stage
inoperable primary lung cancer. Here we report a thorough description of the prognostic …

[HTML][HTML] Metabolic volume parameters based on different thresholds with baseline 18F-FDG PET/CT as prognostic factors for survival in stage III non-small cell lung …

Y Jie, X Meng, A Gu, X Sun, J Yu - Translational Cancer …, 2017 - tcr.amegroups.org
Background: Concurrent chemo-radiotherapy is recommended as the standard treatment of
stage III non-small-cell lung cancer (NSCLC) patients. However, the 5-year survival has not …

Predictors of nodal and metastatic failure in early stage non–small-cell lung cancer after stereotactic body radiation therapy

A Cerra-Franco, S Liu, M Azar, K Shiue, S Freije… - Clinical lung cancer, 2019 - Elsevier
Abstract Introduction/Background Many patients with early stage non–small-cell lung cancer
(ES-NSCLC) undergoing stereotactic body radiation therapy (SBRT) develop metastases …

Early metabolic response evaluation after stereotactic radiotherapy for lung cancer: pilot experience with 18F-fluorodeoxyglucose positron emission tomography …

M Dahele, M Freeman, S Pearson, A Brade, BCJ Cho… - Clinical oncology, 2011 - Elsevier
The early response of lung tumours to stereotactic radiotherapy was prospectively evaluated
with 18F-fluorodeoxyglucose positron emission tomography-computed tomography. Three …

Imaging characteristics of local recurrences after stereotactic body radiation therapy for stage I non‐small cell lung cancer: Evaluation of mass‐like fibrosis

S Hayashi, H Tanaka, H Hoshi - Thoracic cancer, 2015 - Wiley Online Library
Background This study aimed to evaluate stereotactic body radiation therapy (SBRT) in
patients with stage I non‐small cell lung cancer (NSCLC) in terms of radiation‐induced …

18F-FDG PET/CT biomarkers as predictors of long term outcomes and survival rates in patients with high risk malignant pulmonary masses/nodules treated with …

RR Boktor, SU Berlangieri, E Lau, A Lim… - Annals of Nuclear …, 2024 - Springer
Introduction Stereotactic ablative body radiotherapy (SABR) is a standard treatment option
for patients with malignant pulmonary masses (including primary and metastatic lesions) …

Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non …

VJ Nair, R MacRae, A Sirisegaram… - International Journal of …, 2014 - Elsevier
Purpose The aim of this study was to determine whether the preradiation maximum
standardized uptake value (SUV max) of the primary tumor for [18 F]-fluoro-2-deoxy-glucose …

Prognostic value of volumetric metabolic parameter changes determined by during and after radiotherapy‐based 18F‐FDG PET/CT in stage III non‐small cell lung …

HHW Chen, WC Su, HR Guo, BF Lee… - The Kaohsiung journal …, 2019 - Wiley Online Library
The aim of this prospective study was to evaluate the prognostic value of volumetric
metabolic parameters assessed by during and after radiation‐based therapy 18F‐FDG …

Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy

J Hörner-Rieber, D Bernhardt, J Dern, L König… - Radiotherapy and …, 2017 - Elsevier
Background and purpose To investigate the prognostic impact of different histological
subtypes of non-small cell lung cancer (NSCLC) on outcome following stereotactic body …

[HTML][HTML] Stereotactic radiotherapy boost after definite chemoradiation for non-responding locally advanced NSCLC based on early response monitoring 18F-FDG-PET …

TWH Meijer, R Wijsman, EA Usmanij… - Physics and imaging in …, 2018 - Elsevier
Background and purpose Prognosis of locally advanced non-small cell lung cancer remains
poor despite chemoradiation. This planning study evaluated a stereotactic boost after …